Hypertension in Autosomal Dominant Polycystic Kidney Disease

Advances in Chronic Kidney Disease

Volumn 17, Issue 2, 2010, Pages 153-163

  Chapman, Arlene B ^a   Stepniakowski, Konrad ^a   Rahbari Oskoui, Frederic ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autosomal dominant polycystic kidney disease; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; NITRIC OXIDE; PLACEBO; POLYCYSTIN 1; POLYCYSTIN 2; TELMISARTAN;

CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; ENDOTHELIUM CELL; GENE EXPRESSION; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; PKD1 GENE; PKD2 GENE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; HUMANS; HYPERTENSION, RENAL; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENIN-ANGIOTENSIN SYSTEM;

EID: 77449122715     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2010.01.001     Document Type: Review

References (79)

1. Gabow P.A. Autosomal dominant polycystic kidney disease. N Engl J Med 329 (1993) 332-342
2. Torres V.E., and Harris P.C. Autosomal dominant polycystic kidney disease: The last 3 years. Kidney Int 76 (2009) 149-168
3. Chapman A.B. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: Insights from the CRISP and HALT-PKD studies. Clin J Am Soc Nephrol 3 (2008) 1197-1204
4. Perrone R.D., Ruthazer R., and Terrin N.C. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: Contribution of extrarenal complications to mortality. Am J Kidney Dis 38 (2001) 777-784
5. Rahman E., Niaz F.A., Al-Suwaida A., et al. Analysis of causes of mortality in patients with autosomal dominant polycystic kidney disease: A single center study. Saudi J Kidney Dis Transpl 20 (2009) 806-810
6. Chang M.Y., Kuok C.M., Chen Y.C., et al. Comparison of intracerebral hemorrhage and subarachnoid hemorrhage in patients with autosomal-dominant polycystic kidney disease. Nephron Clin Pract 114 (2009) c158-c164
7. Chapman A.B., Guay-Woodford L.M., Grantham J.J., et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 64 (2003) 1035-1045
8. Chapman A.B., and Gabow P.A. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int Suppl 61 (1997) S71-S73
9. Schrier R.W. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 20 (2009) 1888-1893
10. Iglesias C.G., Torres V.E., Offord K.P., et al. Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. Am J Kidney Dis 2 (1983) 630-639
11. Gabow P.A., Johnson A.M., Kaehny W.D., et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 41 (1992) 1311-1319
12. Boulter C., Mulroy S., Webb S., et al. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc Natl Acad Sci U S A 98 (2001) 12174-12179
13. Wu G., Markowitz G.S., Li L., et al. Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet 24 (2000) 75-78
14. McGrath J., Somlo S., Makova S., et al. Two populations of node monocilia initiate left-right asymmetry in the mouse. Cell 114 (2003) 61-73
15. Kim K., Drummond I., Ibraghimov-Beskrovnaya O., et al. Polycystin 1 is required for the structural integrity of blood vessels. Proc Natl Acad Sci U S A 97 (2000) 1731-1736
16. Lantinga-van Leeuwen I.S., Dauwerse J.G., Baelde H.J., et al. Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet 13 (2004) 3069-3077
17. Lu W., Peissel B., Babakhanlou H., et al. Perinatal lethality with kidney and pancreas defects in mice with a targetted Pkd1 mutation. Nat Genet 17 (1997) 179-181
18. Pennekamp P., Karcher C., Fischer A., et al. The ion channel polycystin-2 is required for left right axis determination in mice. Curr Biol 4 (2002) 938-943
19. Hassane S., Claij N., Lantinga-van Leeuwen I.S., et al. Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse model. Arterioscler Thromb Vasc Biol 27 (2007) 2177-2183
20. Qian Q., Li M., Cai Y., et al. Analysis of the polycystins in aortic vascular smooth muscle cells. J Am Soc Nephrol 14 (2003) 2280-2287
21. Qian Q., Hunter L.W., Li M., et al. Pkd2 haploinsufficiency alters intracellular calcium regulation in vascular smooth muscle cells. Hum Mol Genet 12 (2003) 1875-1880
22. Gao Z., Joseph E., Ruden D.M., et al. Drosophila Pkd2 is haploid-insufficient for mediating optimal smooth muscle contractility. J Biol Chem 279 (2004) 14225-14231
23. Nauli S.M., Kawanabe Y., Kaminski J.J., et al. Endothelial cilia are fluid shear sensors that regulate calcium signaling and nitric oxide production through polycystin-1. Circulation 117 (2008) 1161-1171
24. Abou Alaiwi W.A., Takahashi M., Mell B.R., et al. Ciliary polycystin-2 is a mechanosensitive calcium channel involved in nitric oxide signaling cascades. Circ Res 104 (2009) 860-869
25. Fick-Brosnahan G.M., Tran Z.V., Johnson A.M., et al. Progression of autosomal-dominant polycystic kidney disease in children. Kidney Int 59 (2001) 1654-1662
26. Rizk D., Jurkovitz C., Veledar E., et al. Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol 4 (2009) 560-566
27. Ivy D.D., Shaffer E.M., Johnson A.M., et al. Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5 (1995) 2032-2036
28. Cadnapaphornchai M.A., McFann K., Strain J.D., et al. Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int 74 (2008) 1192-1196
29. Seeman T., Dusek J., Vondrichova H., et al. Ambulatory blood pressure correlates with renal volume and number of renal cysts in children with autosomal dominant polycystic kidney disease. Blood Press Monit 8 (2003) 107-110
30. Seeman T., Dusek J., Vondrak K., et al. Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 53 (2004) 629-634
31. Torres V.E. Role of vasopressin antagonists. Clin J Am Soc Nephrol 3 (2008) 1212-1218
32. Doulton T.W., Saggar-Malik A.K., He F.J., et al. The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens 24 (2006) 939-945
33. Chapman A.B., Johnson A.M., Rainguet S., et al. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 8 (1997) 1292-1297
34. Valero F.A., Martinez-Vea A., Bardaji A., et al. Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 10 (1999) 1020-1026
35. Turkmen K., Oflaz H., Uslu B., et al. Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: From impaired tubules to impaired carotid and coronary arteries. Clin J Am Soc Nephrol 3 (2008) 986-991
36. Ecder T., and Schrier R.W. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol 5 (2009) 221-228
37. Martinez-Vea A., Bardaj A., Gutierrez C., et al. Exercise blood pressure, cardiac structure, and diastolic function in young normotensive patients with polycystic kidney disease: A prehypertensive state. Am J Kidney Dis 44 (2004) 216-223
38. Azurmendi P.J., Fraga A.R., Galan F.M., et al. Early renal and vascular changes in ADPKD patients with low-grade albumin excretion and normal renal function. Nephrol Dial Transplant 24 (2009) 2458-2463
39. Kocaman O., Oflaz H., Yekeler E., et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 43 (2004) 854-860
40. Rong S., Jin X., Ye C., et al. Carotid vascular remodelling in patients with autosomal dominant polycystic kidney disease. Nephrology (Carlton) 14 (2009) 113-117
41. Wang D., Iversen J., Wilcox C.S., et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 64 (2003) 1381-1388
42. Turgut F., Oflaz H., Namli S., et al. Ambulatory blood pressure and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease. Ren Fail 29 (2007) 979-984
43. Wang D., Iversen J., and Strandgaard S. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 11 (2000) 1371-1376
44. Serra A.L., Kistler A.D., Poster D., et al. Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol 8 (2007) 13
45. Schrier R.W., Johnson A.M., McFann K., et al. The role of parental hypertension in the frequency and age of diagnosis of hypertension in offspring with autosomal-dominant polycystic kidney disease. Kidney Int 64 (2003) 1792-1799
46. Parfrey P.S., and Barrett B.J. Hypertension in autosomal dominant polycystic kidney disease. Curr Opin Nephrol Hypertens 4 (1995) 460-464
47. Chapman A.B., Torres V.E., Perrone R.D., et al. The HALT Polycystic Kidney Disease Trials-Design and Implementation. Clin J Am Soc Nephrol 5 (2010) 102-109
48. Rahbari-Oskoui F., Miskulin D.C., Fielder O., et al. Reproducibility of ambulatory blood pressure monitoring (ABPM) in hypertensive (HBP) autosomal dominant polycystic kidney disease (ADPKD). J Am Soc Nephrol 19 (2008) 122A
49. Schrier R., McFann K., Johnson A., et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol 13 (2002) 1733-1739
50. Idrizi A., Barbullushi M., Strakosha A., et al. The relation of hypertension, renal function and cardiovascular events in autosomal dominant polycystic kidney disease. G Ital Nefrol 24 (2007) 595-599
51. Ramunni A., Brescia P., Quaranta D., et al. Cutaneous microcirculation is impaired in early autosomal dominant polycystic kidney disease. Nephron Clin Pract 113 (2009) c71-c75
52. Covic A., Mititiuc I., Gusbeth-Tatomir P., et al. The reproucibility of the circadian BP rhythm in treated hypertensive patients with polycystic kidney disease and mild chronic renal impairment-A prospective ABPM study. J Nephrol 15 (2002) 497-506
53. Martinez-Vea A., Valero F.A., Bardaji A., et al. Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: Influence of blood pressure and humoral and neurohormonal factors. Am J Nephrol 20 (2000) 193-200
54. Bardaji A., Martinez-Vea A., Valero A., et al. Cardiac involvement in autosomal-dominant polycystic kidney disease: A hypertensive heart disease. Clin Nephrol 56 (2001) 211-220
55. Levin A., Singer J., Thompson C.R., et al. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27 (1996) 347-354
56. Lumiaho A., Ikaheimo R., Miettinen R., et al. Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. Am J Kidney Dis 38 (2001) 1208-1216
57. Lumiaho A., Pihlajamaki J., Hartikainen J., et al. Insulin resistance is related to left ventricular hypertrophy in patients with polycystic kidney disease type 1. Am J Kidney Dis 41 (2003) 1219-1224
58. Fick-Brosnahan G.M., Belz M.M., McFann K.K., et al. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: A longitudinal study. Am J Kidney Dis 39 (2002) 1127-1134
59. Chapman A.B., Johnson A.M., Gabow P.A., et al. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5 (1994) 1349-1354
60. Grantham J.J., Chapman A.B., and Torres V.E. Volume progression in autosomal dominant polycystic kidney disease: The major factor determining clinical outcomes. Clin J Am Soc Nephrol 1 (2006) 148-157
61. Chapman A.B., Johnson A., Gabow P.A., et al. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323 (1990) 1091-1096
62. Kondo A., Akakura K., and Ito H. Assessment of renal function with color Doppler ultrasound in autosomal dominant polycystic kidney disease. Int J Urol 8 (2001) 95-98
63. Torres V.E., King B.F., Chapman A.B., et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2 (2007) 112-120
64. Graham P.C., and Lindop G.B. The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int 33 (1988) 1084-1090
65. Torres V.E., Wilson D.M., Burnett Jr. J.C., et al. Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc 66 (1991) 1010-1017
66. Watson M.L., Macnicol A.M., Allan P.L., et al. Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int 41 (1992) 206-210
67. Ecder T., Edelstein C.L., Fick-Brosnahan G.M., et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 21 (2001) 98-103
68. Wang D., and Strandgaard S. The pathogenesis of hypertension in autosomal dominant polycystic kidney disease. J Hypertens 15 (1997) 925-933
69. Torres V.E., Donovan K.A., Scicli G., et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int 42 (1992) 364-373
70. Wang D., Strandgaard S., Borresen M.L., et al. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis 51 (2008) 184-191
71. McPherson E.A., Luo Z., Brown R.A., et al. Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol 15 (2004) 493-500
72. Stepniakowski K.T., Gerron G.G., and Chapman A.B. Dissociation between systemic, adrenal, and renal response to angiotensin converting enzyme inhibition (Enalapril (En) 20 mg/day), angiotensin receptor blocker (Losartan (Los) 50 mg/day) vs combination therapy (En/Los) in subjects with autosomal dominant polycystic kidney disease (PKD) during equimolar intravenous angiotensin I (Ang I) and angtiotensin II (Ang II) infusion. J Am Soc Nephrol 13 (2002) 507a-508a
73. Stepniakowski K.T., Gerron G.G., and Chapman A.B. Basal systemic, adrenal and renal responses to angiotensin converting enzyme inhibitor (Enalapril (En) 20 20 mg), angiotensin receptor blocker (Losartan (Los) 50 mg) vs. combination therapy in autosomal dominant polycystic kidney disease (PKD). J Am Soc Nephrol 13 (2002) 508a
74. Maschio G., Alberti D., Janin G., et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334 (1996) 939-945
75. Klahr, S, Breyer, JA, Beck GJ, et al: Dietary protein restriction, blood pressure control and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol 5:2037-2047, 1995
76. Nutahara K., Higashihara E., Horie S., et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 99 (2005) c18-c23
77. Jafar T., Stark P.C., Schmid C.H., et al. The effect of angiotensin-converting enzyme inhibitors on progression of polycystic kidney disease (PKD). Kidney Int 6 (2005) 265-271
78. Torres V.E., Schrier R.W., Chapman A.B., et al. Achievement and Maintenance of Blood Pressure Targets in HALT-PKD. J Am Soc Nephrol 20 (2009) 497A
79. Torres V.E., Schrier R.W., Chapman A.B., et al. HALT-PKD clinical trials, baseline parameters. J Am Soc Nephrol 20 (2009) 499A